BRPI0603206A - modulação de receptores ativados proliferador de peroxisoma - Google Patents

modulação de receptores ativados proliferador de peroxisoma

Info

Publication number
BRPI0603206A
BRPI0603206A BRPI0603206-0A BRPI0603206A BRPI0603206A BR PI0603206 A BRPI0603206 A BR PI0603206A BR PI0603206 A BRPI0603206 A BR PI0603206A BR PI0603206 A BRPI0603206 A BR PI0603206A
Authority
BR
Brazil
Prior art keywords
proliferator activated
activated receptor
peroxisome proliferator
receptor modulation
reductase
Prior art date
Application number
BRPI0603206-0A
Other languages
English (en)
Inventor
Rong-Hwa Lin
Lee-Ming Chuang
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Publication of BRPI0603206A publication Critical patent/BRPI0603206A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)

Abstract

MODULAçãO DE RECPTORES ATIVADOS POR PROLIFERADOR DE PEROXISOMA. A presente invenção refere-se a um método de tratamento de uma doença relacionada com recptores ativados proliferadores de peroxisoma por administração a um indivíduo que necessita de uma quantidade eficaz de um modulador de 15-ceto prostaglandina<sym>- redutase. Também revelados são os métodos de identificação de um composto para a inibição de atividade da redutase e de diminuição de níveis de glicose no sangue por administração a um indivíduo de uma quantidade eficaz de um inibidor de redutase.
BRPI0603206-0A 2005-08-12 2006-08-14 modulação de receptores ativados proliferador de peroxisoma BRPI0603206A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70789705P 2005-08-12 2005-08-12

Publications (1)

Publication Number Publication Date
BRPI0603206A true BRPI0603206A (pt) 2007-05-15

Family

ID=37737230

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0603206-0A BRPI0603206A (pt) 2005-08-12 2006-08-14 modulação de receptores ativados proliferador de peroxisoma

Country Status (16)

Country Link
US (1) US20070037193A1 (pt)
EP (1) EP1803809A3 (pt)
JP (1) JP2007061093A (pt)
KR (1) KR20080014936A (pt)
CN (1) CN1916167A (pt)
AR (1) AR054909A1 (pt)
AU (1) AU2006203479A1 (pt)
BR (1) BRPI0603206A (pt)
CA (1) CA2553115A1 (pt)
CO (1) CO5780135A1 (pt)
IL (1) IL177407A0 (pt)
MX (1) MXPA06009161A (pt)
NO (1) NO20063652L (pt)
SG (1) SG130141A1 (pt)
TW (1) TW200741003A (pt)
ZA (1) ZA200606661B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2431634C2 (ru) * 2005-03-11 2011-10-20 Говард Флори Инститьют Оф Експериментл Физиолоджи Энд Медсин Соединения флавоноидов и их применение
WO2009026657A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
JP5584680B2 (ja) * 2008-05-28 2014-09-03 ビーエーエスエフ ソシエタス・ヨーロピア ペルオキシソーム増殖の増加を評価する手段及び方法
CA2747811A1 (en) * 2008-12-22 2010-07-01 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds
US8918198B2 (en) * 2009-01-21 2014-12-23 George Atanasoff Methods and systems for control of a surface modification process
EA015364B1 (ru) * 2009-03-18 2011-06-30 Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) 6,6'-диизопропил-8,8'-диметил-2,2'-динитро-3,3'-бис(трифторметил)- 3н,3'н-[9,9']ди[бензо(f)хроменил]-5,10,5',10'-тетраол, обладающий противоопухолевой и противогрибковой активностью, и способ его получения
US9752191B2 (en) * 2009-07-09 2017-09-05 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
CN101948458B (zh) * 2010-09-07 2012-11-07 中国药科大学 具有抗肿瘤活性的黄芩素衍生物及在医药上的应用
CN102964322A (zh) * 2012-12-12 2013-03-13 中国药科大学 异黄酮或类黄酮脂肪醚类衍生物、其制备方法和医药用途
JP7029777B2 (ja) * 2016-03-28 2022-03-04 国立大学法人金沢大学 アンドロゲン依存性又は非依存性前立腺癌細胞の抑制用の組成物及びそれを含有する前立腺癌の医薬製剤
CN107496414A (zh) * 2017-09-21 2017-12-22 上海华堇生物技术有限责任公司 柽柳黄素的药物用途
CN112645922B (zh) * 2020-12-24 2022-01-07 中国人民解放军空军军医大学 香豆素类化合物、制备方法及应用
CN115894422A (zh) * 2022-12-26 2023-04-04 上海中医药大学 PPARγ激动剂及其组合和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543550B1 (fr) * 1983-04-01 1985-08-09 Cortial Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
US4587260A (en) * 1984-06-21 1986-05-06 Warner-Lambert Company Dibenzalacetone and benzylcinnamate as non-steroidal anti-inflammatory compounds and compositions thereof
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ATE222762T1 (de) * 1995-11-17 2002-09-15 Upjohn Co 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus
EP1183370A2 (en) * 1999-05-20 2002-03-06 Incyte Genomics, Inc. Human oxidoreductase proteins
KR100788226B1 (ko) * 2000-03-24 2007-12-26 수캄포 아게 15-케토-프로스타글란딘 또는 이의 유도체를 포함하는세포자연사 억제 조성물
EP1402026A2 (en) * 2000-04-18 2004-03-31 Millennium Pharmaceuticals, Inc. 39228, a human alcohol dehydrogenase and uses therefor
WO2001080855A1 (en) * 2000-04-27 2001-11-01 Geron Corporation Telomerase inhibitors and methods of their use
US7326734B2 (en) * 2003-04-01 2008-02-05 The Regents Of The University Of California Treatment of bladder and urinary tract cancers

Also Published As

Publication number Publication date
NO20063652L (no) 2007-02-13
JP2007061093A (ja) 2007-03-15
CN1916167A (zh) 2007-02-21
IL177407A0 (en) 2006-12-31
CO5780135A1 (es) 2007-07-31
EP1803809A2 (en) 2007-07-04
KR20080014936A (ko) 2008-02-15
AR054909A1 (es) 2007-07-25
ZA200606661B (en) 2008-05-28
AU2006203479A1 (en) 2007-03-01
TW200741003A (en) 2007-11-01
SG130141A1 (en) 2007-03-20
CA2553115A1 (en) 2007-02-12
EP1803809A3 (en) 2007-12-19
US20070037193A1 (en) 2007-02-15
MXPA06009161A (es) 2007-03-21

Similar Documents

Publication Publication Date Title
BRPI0603206A (pt) modulação de receptores ativados proliferador de peroxisoma
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CL2009000967A1 (es) Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente.
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
ECSP045501A (es) Moduladores de receptores nucleares de hormonas esteroideas triciclicos
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CR20110016A (es) Compuestos quimicos 251
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
BRPI0509207A (pt) moduladores canabinóides de tetraidro-indazol
BRPI0407485A (pt) utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina
MA34474B1 (fr) Agonistes de gpr40
MX2009002924A (es) Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
BR112021015238A8 (pt) Novos anticorpos de ligação a cd40
MX2007004765A (es) Compuestos y metodos que modulan la actividad de la trombopoyetina.
CR11723A (es) Agente para tratar enfermedad
ECSP077387A (es) Composiciones que contienen piperacilina, tazobactam y un ácido aminocarboxílico en un diluyente de lactato de sodio
BRPI0509710A8 (pt) Formulação de liberação controlada para administração oral de inibidor de hmg-coa redutase e método para preparação da mesma
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BR112012006010A2 (pt) composto de glicina
BRPI0607084A2 (pt) uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
UY30675A1 (es) Metodos para el tratamiento de la depresion

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]